Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sangamo Therapeutics Inc

0.5269
-0.0081-1.51%
Post-market: 0.53030.0034+0.65%16:50 EDT
Volume:1.97M
Turnover:1.05M
Market Cap:125.19M
PE:-1.40
High:0.5417
Open:0.5300
Low:0.5200
Close:0.5350
Loading ...

Sangamo Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
31 Dec 2024

SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate

Zacks
·
31 Dec 2024

Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $2 From $3, Keeps Equalweight Rating

MT Newswires Live
·
31 Dec 2024

Sangamo cash an overhang after Pfizer termination, says Truist

TIPRANKS
·
31 Dec 2024

TD Cowen ‘disappointed’ Pfizer ended Sangamo collaboration

TIPRANKS
·
31 Dec 2024

Penny Stock Sangamo (SGMO) Nosedives as Pfizer Terminates Partnership

TIPRANKS
·
31 Dec 2024

CompoSecure, Cemtrex And 3 Stocks To Watch Heading Into Tuesday

Benzinga
·
31 Dec 2024

24H | Faraday Future Soars Another 21%; BigBear.ai Jumps 2%; Sangamo Shares Plunge 60%

Tiger Newspress
·
31 Dec 2024

Sangamo decline on Pfizer collaboration decision ‘overdone’, says Barclays

TIPRANKS
·
31 Dec 2024

Barclays Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)

TIPRANKS
·
31 Dec 2024

Stocks to Watch: Affinity Bancshares, Sangamo Therapeutics, CompoSecure

Dow Jones
·
31 Dec 2024

Sangamo Shares Plunge After Pfizer Ends Hemophilia A Gene Therapy Deal

Reuters
·
31 Dec 2024

Sangamo Therapeutics Shares Sinks After Pfizer Pulls Out of Potential Hemophilia A Therapy Study

MT Newswires Live
·
31 Dec 2024

BUZZ-Sangamo Therapeutics plunges after Pfizer terminates partnership

Reuters
·
31 Dec 2024

Sangamo down 31% at $1.61 after Pfizer decision to terminate collaboration

TIPRANKS
·
31 Dec 2024

Sangamo to reclaim hemophilia A therapy rights post Pfizer termination

Reuters
·
31 Dec 2024

BRIEF-Sangamo Therapeutics To Regain Full Rights To Hemophilia A Gene Therapy Program Following Pfizer’S Decision To Cease Development Of Giroctocogene Fitelparvovec

Reuters
·
31 Dec 2024

Sangamo to regain rights to giroctocogene fitelparvovec from Pfizer

TIPRANKS
·
31 Dec 2024

Sangamo Therapeutics Inc: Collaboration and License Agreement With Pfizer Will Terminate Effective April 21, 2025

THOMSON REUTERS
·
31 Dec 2024

Sangamo Therapeutics: Intends to Explore Options to Advance Program, Including Seeking Potential New Collaboration Partner

THOMSON REUTERS
·
31 Dec 2024